INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 285 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $261,231 | +0.2% | 5,015 | +21.8% | 0.06% | -39.4% |
| Q2 2023 | $260,688 | -73.3% | 4,117 | -80.4% | 0.10% | -71.2% |
| Q3 2022 | $978,000 | -45.5% | 21,021 | -33.1% | 0.34% | -56.1% |
| Q2 2022 | $1,794,000 | -14.4% | 31,425 | -8.3% | 0.78% | -20.0% |
| Q1 2022 | $2,096,000 | +45.4% | 34,260 | +24.3% | 0.98% | +305.0% |
| Q4 2021 | $1,442,000 | -51.8% | 27,553 | -76.4% | 0.24% | +24.1% |
| Q2 2020 | $2,993,000 | +28.7% | 116,579 | -22.9% | 0.20% | -4.4% |
| Q1 2020 | $2,325,000 | – | 151,239 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |